Literature DB >> 29393120

Prevalence of Chronic Kidney Disease, Thrombotic Cardiovascular Events, and Use of Oral P2Y12 Inhibitors among Veterans.

Manisha Singh1,2, Deepa Raghavan1,2, James S Williams2, Bradley C Martin1, Teresa J Hudson1,2, Richard R Owen2, Nishank Jain1,2.   

Abstract

BACKGROUND: Contemporary prevalence of chronic kidney disease (CKD) and thrombotic cardiovascular (CV) events remains unclear in Veterans enrolled in the Veterans Affairs Health Care System (VA) care. Although oral P2Y12 inhibitors (P2Y12i) are increasingly being prescribed to this patient population, the overall prescription trend for P2Y12i remains unclear.
METHODS: Using national VA corporate warehouse data, we used International Classification of Diseases-9 codes to identify Veterans with CKD, dialysis-dependent CKD, and CV events. VA pharmacy data were used to count P2Y12i prescriptions for the federal fiscal years (FY) 2011 through 2015.
RESULTS: The period prevalence of Veterans with CKD was 378,233 (6.1%). The point prevalence of CKD increased by 49% from 132,979 (2.30%) in FY11 to 213,444 (3.42%) in FY15. The period prevalence of Veterans with dialysis-dependent CKD was 150,298 (2.4%). In all, 128,703 (56.7%) CV events occurred in Veterans with CKD. Veterans with CKD were given 50.1% of prescriptions for clopidogrel, 49.3% for prasugrel, and 60.4% for ticagrelor. In this patient population, year-to-year increases in P2Y12i prescriptions were observed with a dramatic increase in ticagrelor prescriptions.
CONCLUSION: CKD is common among Veterans and its true prevalence is likely being underestimated. The prevalence of dialysis-dependent CKD is higher among Veterans than the non-Veteran US population. CV events are widely co-prevalent and these patients are commonly prescribed P2Y12i. The recent increase in ticagrelor prescriptions in this patient population and large cost differences between the 3 P2Y12i underline the need for future studies to identify the preferred P2Y12i for these patients. The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Cardiovascular; Kidney; Outcomes; P2Y12 inhibitors; Prevalence

Mesh:

Substances:

Year:  2018        PMID: 29393120      PMCID: PMC5969069          DOI: 10.1159/000486647

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  11 in total

1.  Transforming Evidence Generation to Support Health and Health Care Decisions.

Authors:  Robert M Califf; Melissa A Robb; Andrew B Bindman; Josephine P Briggs; Francis S Collins; Patrick H Conway; Trinka S Coster; Francesca E Cunningham; Nancy De Lew; Karen B DeSalvo; Christine Dymek; Victor J Dzau; Rachael L Fleurence; Richard G Frank; J Michael Gaziano; Petra Kaufmann; Michael Lauer; Peter W Marks; J Michael McGinnis; Chesley Richards; Joe V Selby; David J Shulkin; Jeffrey Shuren; Andrew M Slavitt; Scott R Smith; B Vindell Washington; P Jon White; Janet Woodcock; Jonathan Woodson; Rachel E Sherman
Journal:  N Engl J Med       Date:  2016-12-15       Impact factor: 91.245

Review 2.  Renal Replacement Therapy and Incremental Hemodialysis for Veterans with Advanced Chronic Kidney Disease.

Authors:  Kamyar Kalantar-Zadeh; Susan T Crowley; Srinivasan Beddhu; Joline L T Chen; John T Daugirdas; David S Goldfarb; Anna Jin; Csaba P Kovesdy; David J Leehey; Hamid Moradi; Sankar D Navaneethan; Keith C Norris; Yoshitsugu Obi; Ann O'Hare; Tariq Shafi; Elani Streja; Mark L Unruh; Tushar J Vachharajani; Steven Weisbord; Connie M Rhee
Journal:  Semin Dial       Date:  2017-04-18       Impact factor: 3.455

3.  Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.

Authors:  Geoffrey D Barnes; Maggie A Stanislawski; Wenhui Liu; Anna E Barón; Ehrin J Armstrong; P Michael Ho; Andrew Klein; Thomas M Maddox; Brahmajee K Nallamothu; John S Rumsfeld; Thomas T Tsai; Steven M Bradley
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-05-31

Review 4.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.

Authors:  Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

5.  Predictors of hyperkalemia and death in patients with cardiac and renal disease.

Authors:  Nishank Jain; Suman Kotla; Bertis B Little; Rick A Weideman; Emmanouil S Brilakis; Robert F Reilly; Subhash Banerjee
Journal:  Am J Cardiol       Date:  2012-02-18       Impact factor: 2.778

6.  Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.

Authors:  Stefan James; Andrzej Budaj; Philip Aylward; Kristen K Buck; Christopher P Cannon; Jan H Cornel; Robert A Harrington; Jay Horrow; Hugo Katus; Matyas Keltai; Basil S Lewis; Keyur Parikh; Robert F Storey; Karolina Szummer; Daniel Wojdyla; Lars Wallentin
Journal:  Circulation       Date:  2010-08-30       Impact factor: 29.690

7.  Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.

Authors:  Omar K Siddiqi; Kyle J Smoot; Alyssa B Dufour; Kelly Cho; Melissa Young; David R Gagnon; Samantha Ly; Sara Temiyasathit; David P Faxon; J Michael Gaziano; Scott Kinlay
Journal:  Heart       Date:  2015-07-24       Impact factor: 5.994

8.  Kidney disease mortality--Michigan, 1989-2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-03-16       Impact factor: 17.586

9.  Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive 'real-world' patients.

Authors:  Rebecca Gosling; Momina Yazdani; Yasir Parviz; Ian R Hall; Ever D Grech; Julian P Gunn; Robert F Storey; Javaid Iqbal
Journal:  Platelets       Date:  2017-03-07       Impact factor: 3.862

10.  Comparison of outcomes for veterans receiving dialysis care from VA and non-VA providers.

Authors:  Virginia Wang; Matthew L Maciejewski; Uptal D Patel; Karen M Stechuchak; Denise M Hynes; Morris Weinberger
Journal:  BMC Health Serv Res       Date:  2013-01-18       Impact factor: 2.655

View more
  4 in total

1.  Accurate Medication Adherence Measurement Using Administrative Data for Frequently Hospitalized Patients.

Authors:  Rafia S Rasu; Suzanne L Hunt; Junqiang Dai; Huizhong Cui; Milind A Phadnis; Nishank Jain
Journal:  Hosp Pharm       Date:  2020-06-02

2.  Home run-results of a chronic kidney disease Telemedicine Patient Education Study.

Authors:  Andrea M Easom; Ashutosh M Shukla; Dumitru Rotaru; Songthip Ounpraseuth; Sudhir V Shah; John M Arthur; Manisha Singh
Journal:  Clin Kidney J       Date:  2019-08-22

3.  Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis.

Authors:  Nishank Jain; Suzanne L Hunt; Huizhong Cui; Milind A Phadnis; Jonathan D Mahnken; Theresa I Shireman; Junqiang Dai; Jawahar L Mehta; Rafia S Rasu
Journal:  Cardiovasc Drugs Ther       Date:  2019-10       Impact factor: 3.727

4.  Trends in Illness Severity, Hospitalization, and Mortality for Community-Onset Pneumonia at 118 US Veterans Affairs Medical Centers.

Authors:  Barbara E Jones; Jian Ying; Mckenna R Nevers; Patrick R Alba; Olga V Patterson; Kelly S Peterson; Elizabeth Rutter; Matthew A Christensen; Sarah Stern; Makoto M Jones; Adi Gundlapalli; Nathan C Dean; Matthew C Samore; Tome Greene
Journal:  J Gen Intern Med       Date:  2022-03-09       Impact factor: 5.128

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.